Nanobiotix Secures Cash Runway into 2029 with €86.1M Offering Completion
NBTX has more than doubled off its 52-week low of $4.062.
Summary
Nanobiotix announced the completion of its €86.1 million follow-on offering, extending its cash runway into 2029 and providing financial stability for its clinical development programs.
Key Events · Financing and Capital Events · NBTX
-
Offering Completion
Successfully completed a follow-on offering in May 2026, raising approximately €86.1 million in gross proceeds.
-
Extended Cash Runway
The company now has sufficient cash and cash equivalents to fund operations into 2029, significantly de-risking its operations.
-
Clinical Data Update
Reiterated promising Part 1 data from the Phase 2 CONVERGE study in NSCLC, showing an 85.7% overall response rate and 57.1% complete response rate.
-
Regulatory Progress
FDA accepted a protocol amendment for the pivotal Phase 3 NANORAY-312 study, eliminating an interim analysis and modifying the final analysis for an earlier readout.
Analysis · NBTX · Life Sciences
This filing confirms the successful completion of Nanobiotix's follow-on offering, raising approximately €86.1 million. Crucially, this capital raise, combined with existing cash, extends the company's operational cash runway into 2029. For a late-clinical stage biotechnology company, securing long-term funding significantly de-risks its development programs and provides stability to advance its pipeline, including the JNJ-1900 (NBTXR3) and Nanoprimer platforms. The update also reiterates positive clinical data and regulatory progress, reinforcing the company's operational momentum.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NBTX was trading at $36.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $4.06 to $57.14. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.